GLPwatch
DUTCH Weight Control in Atrial Fibrillation Study
NCT06184633 · Recruiting
Last updated 2026-05-28This clinical trial tests whether a weight control program helps people with atrial fibrillation and obesity manage their weight over 12 months.
Status Recruiting Currently enrolling participants.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, triple-blind treatment study
Participants 280 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2024-07 · est. completion 2027-05
Where 1 site · Netherlands
What this study is testing ClinicalTrials.gov NCT06184633 ↗
Description as written by the study sponsor.
Quantify the effect of an innovative weight loss management on rhythm control.
Treatments tested
- Semaglutide 3.2 MG/ML Drug
Intervention arm receives semaglutide in addition to combined lifestyle intervention
- Placebo Drug
Control arm receives placebo in addition to combined lifestyle intervention
| Main thing measured | The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome |
|---|---|
| Sponsor | Rijnstate Hospital |
| Conditions studied | Atrial Fibrillation, Obesity, Weight Loss |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06184633 ↗